HHC Gummy Sold as THC: A Dissociative ER Case With Serum Proof | Research

The takeaway

A gummy marketed as THC was linked to a dissociative-like episode and GI symptoms, and blood testing found only HHC isomers. Symptoms cleared within 8 hours.

Read this if you want to know what an analytically confirmed HHC intoxication looked like in a real hospital case.

8 hours
until symptoms resolved after ingestion in this single analytically confirmed HHC case

What the researchers found

In this individual case, a 32-year-old man developed a dissociative-like neurologic syndrome plus gastrointestinal symptoms after ingesting a single gummy sold as a THC product. Serum testing analytically confirmed exposure to two HHC isomers (9R-HHC and 9 S-HHC), with no other pharmaceutical or psychoactive substances detected. Symptoms resolved within 8 hours with supportive care.

Why it matters

HHC entered global markets around 2021 and has been detected in unregulated cannabis products, but clinical descriptions with laboratory confirmation have been limited. This 2026 medical toxicology case report focuses on what acute HHC intoxication can look like in a real hospital presentation when exposure is analytically verified. It also reflects a practical measurement problem in emergent cannabinoids: product labeling can be unreliable, and routine toxicology panels may miss newer compounds unless targeted testing is performed.

The numbers in context

• Time from ingestion to hospital presentation: 1.5 hours (rapid onset after a single edible exposure in this case).

• Heart rate: 118 beats per minute (sinus tachycardia, a clear elevation).

• Respiratory rate: 24 breaths per minute (tachypnoea, above typical adult resting range).

• Symptom duration: resolved within 8 hours of ingestion (short-lived course in this single case).

How the study worked

This is a case report, meaning it documents one person’s clinical course in detail rather than comparing groups. Clinicians recorded symptoms and vital signs after a 32-year-old man presented soon after eating a gummy marketed as THC. Standard lab investigations (haematology and biochemistry) were checked and were reported as normal. Serum testing was used to identify HHC isomers (9R-HHC and 9 S-HHC) and to look for other pharmaceutical or psychoactive substances. The main weakness is that one case cannot show how common this reaction is, what the typical severity looks like, or whether HHC alone explains every symptom in broader populations.

Who was studied

N=1 adult male aged 32, hospital presentation, Country not specified in abstract.

What this study cannot tell us

Only one patient was described, so the report cannot establish frequency, typical dose-response, or a predictable clinical course. The amount of HHC in the gummy was not quantified in the abstract, which makes it hard to connect symptoms to an exposure level. This describes 1 patient(s). Individual cases cannot establish patterns or causation.

How to read the evidence

Rated preliminary: a single case report with lab-confirmed HHC exposure and no comparison group cannot show frequency or typical risk.

When this study was published

Published in 2026, reflecting the post-2021 market wave of HHC products and the ongoing gap between product labeling and what targeted testing can detect. It also reflects current realities where routine tox screens may miss newer cannabinoids unless specifically tested.

The bigger picture

A headline might read like “HHC causes dissociative neurotoxicity,” but this paper only documents one analytically confirmed exposure and a time-linked clinical syndrome in that individual. The standout detail is the serum confirmation of both 9R-HHC and 9 S-HHC with no other detected psychoactive substances, which narrows (but does not eliminate) alternative explanations such as undisclosed co-exposures or contaminants not covered by the testing method. The case also spotlights a labeling gap: the product was sold as THC, yet testing identified HHC isomers, so the clinical question becomes about what was actually consumed rather than what was marketed. The authors place this single presentation alongside prior case descriptions that have included seizures, hallucinations, mydriasis, dyskinesia, and acute psychosis, but this report does not quantify how often those outcomes occur or under what conditions.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

What serum concentrations of 9R-HHC and 9 S-HHC are associated with specific neurologic presentations (for example, dissociation, dysarthria, or seizures) in larger series of patients?
How often do products sold as “THC” contain HHC isomers, and how does that vary by region and supply chain?
Do different HHC isomer ratios (9R vs 9 S) correlate with different symptom profiles or duration of toxicity?

Common questions

Was this reaction linked to HHC alone, or could it have been something else in the gummy?

Serum testing detected two HHC isomers (9R-HHC and 9S-HHC) and did not detect other pharmaceutical or psychoactive substances using the authors’ analysis. That narrows alternative explanations, but a case report cannot rule out every possible contaminant or untested co-exposure.

How fast did symptoms start and what did the hospital exam show in this case?

The patient presented about 1.5 hours after eating one gummy. Documented findings included nausea and vomiting, confusion with an apparent dissociative state, slurred speech, mydriasis, sinus tachycardia (118 bpm), and tachypnoea (24 breaths per minute), without an objective focal neurologic deficit.

How long did the HHC-related symptoms last in this case report?

Symptoms resolved within 8 hours of ingestion with supportive management, and routine haematology and biochemistry tests were reported as normal.

Read the original research

Dissociative-like Neurotoxicity Following Analytically Confirmed Exposure To Hexahydrocannabinol (HHC).

Journal of medical toxicology : official journal of the American College of Medical Toxicology, 22(1), 77-80

Journal of Medical Toxicology is a peer-reviewed specialty journal from the American College of Medical Toxicology focused on clinical toxicology and poisoning cases.

View on PubMed ↗Publisher’s paper ↗

Citation

Greene, Shaun L; Fawcett, Rebecca; Castle, Jared; Koutsogiannis, Zeff. (2026). Dissociative-like Neurotoxicity Following Analytically Confirmed Exposure To Hexahydrocannabinol (HHC).. Journal of medical toxicology : official journal of the American College of Medical Toxicology, 22(1), 77-80. https://doi.org/10.1007/s13181-025-01102-8